Weight Loss
Semaglutide
The original blockbuster GLP-1. Widely available, well-studied, mainstream.
8 vendor listings tracked on VialVerdict.
Open Semaglutide pageThis comparison captures GLP-1 researchers who already know Semaglutide and are evaluating newer Retatrutide vendor listings.
Quick answer
Semaglutide is a GLP-1 agonist with broader market recognition, while Retatrutide is a newer investigational triple agonist with faster-changing vendor availability.
Weight Loss
The original blockbuster GLP-1. Widely available, well-studied, mainstream.
8 vendor listings tracked on VialVerdict.
Open Semaglutide pageWeight Loss
The next-generation triple agonist. Showing the strongest weight-loss data in early trials.
12 vendor listings tracked on VialVerdict.
Open Retatrutide page| Signal | Semaglutide | Retatrutide |
|---|---|---|
| Primary research angle | Single GLP-1 pathway research | Triple agonist research |
| Buying check | Confirm stock, testing, vial size, and vendor reviews | Verify product naming, batch/testing details, and availability |
| Best next page | Best Semaglutide vendors | Best Retatrutide vendors |
| VialVerdict coverage | 0 reviews · 8 vendor listings | 0 reviews · 12 vendor listings |
Evidence-led research
A source-backed CLAIM Chain for verifying laboratory independence, accreditation scope, report authenticity, analytical methods, and lot matching.
Read the guideA source-backed evidence ladder for checking vendor identity, regulatory claims, reviews, lot-level testing, laboratory scope, fulfillment, and payment risk.
Read the guide